Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Hague – page 67

1 216 clinical trials in Hague, The Netherlands across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Hague at a glance
1 216
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

1 216 trials in Hague

Open in trial search

Study Comparing Datopotamab Deruxtecan and Docetaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Daiichi Sankyo Inc.

Embolism venous

Not recruiting

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Neuralgia+1

Not recruiting

Study on Lacosamide and Duloxetine for Patients with Chemotherapy-Induced Neuropathic Pain

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Duloxetine
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Prostate cancer

Not recruiting

Study on the Effect of Adding Leuprorelin Acetate to Radiotherapy for Patients with Oligo-recurrent Prostate Cancer with Up to 4 Metastases

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Leuprorelin Acetate
  • Sponsor:Universitair Medisch Centrum Groningen

Embolism venous+1

Not recruiting

Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Plasma cell myeloma

Not recruiting

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Thalassaemia

Not recruiting

Study on the Effects of Mitapivat for Patients with Transfusion-Dependent Alpha or Beta Thalassemia

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Multiple sclerosis

Not recruiting

Study on Personalized Dosing of Natalizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Natalizumab
  • Sponsor:Amsterdam UMC Stichting

Long-Term Follow-Up Study of TX200-TR101 for Patients with Kidney Transplant Rejection

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:TX200-TR101
  • Sponsor:Sangamo Therapeutics Inc.

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on Durvalumab and Rintatolimod for Patients with Metastatic Pancreatic Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Factor IX deficiency

Not recruiting

Title: Study of gene therapy etranacogene dezaparvovec (Hemgenix) in adult patients with moderate to severe Hemophilia B

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Etranacogene Dezaparvovec
  • Sponsor:CSL Behring LLC

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Hague

What the registry says about research in the country

01 Leukemia Research

Innovative clinical trials focusing on Acute Myeloid Leukemia (AML) and associated conditions, evaluating targeted therapies in combination with standard treatments.

  • FLT3 Mutation Studies
  • Combination Therapy Approaches
  • Maintenance Treatment Protocols

Research aims to improve survival rates through personalized treatment strategies for newly diagnosed patients.

02 Lymphoma Studies

Comprehensive research on Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma, investigating novel therapeutic combinations and immunotherapy approaches.

  • High-Grade B-Cell Lymphoma Treatment
  • Immunotherapy Consolidation
  • Relapsed/Refractory Disease Management

Studies focus on improving disease-free survival rates using innovative treatment combinations.

03 Targeted Therapies

Advanced research into targeted therapeutic approaches for hematologic malignancies, combining conventional chemotherapy with novel agents.

  • Immunotherapy Integration
  • Consolidation Strategies
  • Risk-Adapted Treatment Approaches

Trials aim to establish more effective and personalized treatment protocols for high-risk patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.